---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-013509"
form_type: "8-K"
ticker: "OTLK"
cik: "0001649989"
company_name: "Outlook Therapeutics, Inc."
filed_at: "2025-02-14T23:59:59+00:00"
generated_at: "2026-05-26T21:25:57.625157+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Outlook Q1: GAAP EPS $0.72 (fair value gains), adj EPS -$0.89; BLA resubmission on track

## Summary
- GAAP net income $17.4M ($0.72/sh) vs net loss $11.2M; adj net loss $21.6M ($0.89/sh) vs $10.1M ($0.78 loss) prior year.
- BLA resubmission for ONS-5010 (bevacizumab-vikg) targeted for Q1 CY2025; potential FDA approval in Q3 CY2025.
- First commercial launches of LYTENAVA in Germany and UK planned for Q2 CY2025; collaboration with Cencora announced.
- NORSE EIGHT trial missed primary non-inferiority endpoint at week 8; 12-week analysis met non-inferiority margin.

## SEC filing metadata
- accession: 0001104659-25-013509
- form_type: 8-K
- ticker: OTLK
- cik: 0001649989
- company_name: Outlook Therapeutics, Inc.
- filed_at: 2025-02-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649989/000110465925013509/0001104659-25-013509-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649989/000110465925013509/tm256608d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-013509
- JSON: https://secwatch.observer/filing/0001104659-25-013509.json
- Plain text: https://secwatch.observer/filing/0001104659-25-013509.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.